Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Developing an analytical method by HPLC for simultaneous quantification of methylene blue and metformin applied to in vitro skin permeation and retention studies

Full text
Author(s):
Matos, Lisa de Carvalho [1] ; Calixto, Leandro Augusto [1] ; Junqueira Garcia, Maria Teresa [1]
Total Authors: 3
Affiliation:
[1] Fed Univ Sao Paulo Unifesp, Inst Environm Chem & Pharmaceut Sci, Dept Pharmaceut Sci, Rua Sao Nicolau 210, Diadema, SP - Brazil
Total Affiliations: 1
Document type: Journal article
Source: BIOMEDICAL CHROMATOGRAPHY; v. 35, n. 8 MAR 2021.
Web of Science Citations: 0
Abstract

The aim of this study was to develop an HPLC method for simultaneous quantification of metformin (MET) and methylene blue (MB) in in vitro skin permeation/retention studies, in which retention was evaluated in the different layers of the skin {[}stratum corneum (SC) and the viable epidermis + dermis (VE + D)]. The method was validated considering the following parameters: specificity, linearity, quantitation limit (LOQ), recovery, precision and accuracy. Calibration curves were obtained using the following six matrices: methanol, water, methanolic extracts from the SC and VE + D spiked with the drugs and drugs extracted from the SC and VE + D. The precision, accuracy and LOQ of the method were evaluated in water and in VE + D and SC, applying the drug extraction process. The results show that the method is selective and linear for both drugs. The precision and accuracy values, independent of matrix and drug, were below the limit of 15%. The LOQ of MB was defined as 0.4 mu g/ml in the VE + D and SC and 0.8 mu g/ml in water. The LOQ of MET was defined as 0.8 mu g/ml in the VE + D and SC and 0.4 mu g/ml in the water. The recovery of the method was adequate, consistent and reproducible for the concentration range of 0.4-10 mu g/ml for MB (73.3-92.1%) and 0.8-10.0 mu g/mL for MET (72.4-94.4%). This method has a potential application in the development of formulation for skin delivery of MB and MET. (AU)

FAPESP's process: 17/18239-0 - Nanomemulsions as delivery systems of methylene blue and metformin for the treatment of skin cancer: release, in vitro permeation/retention and cytotoxicity studies
Grantee:Maria Teresa Junqueira Garcia
Support Opportunities: Regular Research Grants